Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$25.58 +0.27%

+$0.09 today

Market cap
$1.85B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 0.95M

Average 1.18M

VERA Sales of Investments

Cash received from selling or redeeming investments.

Vera Therapeutics, Inc.NASDAQ: VERA

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments grows, but more slowly than its trailing trend

Q2 FY2026 sales of investments of $131.03M rose 3.9% year over year, behind the +18.2% change in trailing-twelve-month sales of investments. Sequentially, it rose 49.0% from the prior quarter. Over 3 fiscal years it compounded at +86.5% a year.

Context

  • Sales of investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.9% toward the trailing-twelve-month pace of +18.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$131.03M+49.0% QoQ
Last fiscal yearDec 2025
$506.16M+81.4% YoY
LTMJun 2026
$492.8M+18.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.9%——
1 year+81.4%——
3-year CAGR+86.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
506.16M USD
Year-over-year change
+81.4%

Sales of Investments vs competitors

How VERA compares with its peers on the latest reported figures

  • VERA's LTM Jun 2026 sales of investments of $492.8M is the 2nd largest of the 10 companies compared; the peer median is $350M.
  • Its year-over-year change of +18.2% is the 4th highest of 10, against a peer median of -19.5%.
  • Over three fiscal years its annual growth of +86.5% compares with a peer median of +46.4%.
VERA Competitors Peer median
Sales of Investments for VERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$555.15M +110.1%+46.4%7504.0%
VERAVera Therapeutics, Inc.LTM Jun 2026$492.8M +18.2%+86.5%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$385.18M -2.0%+109.8%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$382.74M +65.8%+261.7%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$362.7M +47.6%+438.5%19049.4%
BHVNBiohaven Ltd.LTM Jun 2026$350M -46.3%——
ANABAnaptysBio, Inc.LTM Mar 2026$322.1M -33.7%+1.3%138.6%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$199.64M -27.9%-13.5%43.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$79.8M -19.5%-20.6%953.7%
PHARPharming Group N.V.LTM Mar 2026$34.98M -87.9%—9.5%
Peer median (excluding VERA) $350M-19.5%+46.4%546.2%

Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.61M)(89.06M)(95.99M)(152.15M)(299.62M)
Depreciation & Amortization176K(846K)21K105K468K
Deferred Income Tax(1.8M)0000
Stock-Based Compensation3.01M8.89M11.49M20.8M37.93M
Change in Working Capital3.51M6.75M(5.87M)2.66M22.99M
Accounts Receivables00000
Inventory00000
Accounts Payables475K10.61M(873K)(3.45M)13.91M
Other Working Capital3.04M(3.86M)(5M)6.11M9.08M
Other Non-Cash Items4M6.67M(1.84M)(6.1M)(2.88M)
Operating Cash Flow(23.71M)(67.6M)(92.18M)(134.68M)(241.1M)
Capital Expenditures0(62K)(63K)(972K)(630K)
Acquisitions (Net)796K70.49K000
Purchases of Investments0(148.49M)(224.93M)(711.99M)(310.45M)
Sales of Investments078M185.56M278.96M506.16M
Other Investing Activities(5M)(70.49K)08.97M(800K)
Investing Cash Flow(4.2M)(70.55M)(39.43M)(425.03M)194.29M
Debt Repayment4.92M19.82M24.74M023.34M
Common Stock Issued51.18M86.13M115M632.54M307.48M
Common Stock Repurchased000(13K)0
Dividends Paid00000
Other Financing Activities(2.22M)(4.01M)(6.2M)(25.85M)(21.92M)
Financing Cash Flow53.88M101.93M133.54M606.67M308.9M
Effect of Forex Changes00000
Net Change in Cash25.97M(36.22M)1.93M46.97M262.08M
Free Cash Flow(23.71M)(67.66M)(92.24M)(135.65M)(241.73M)

Vera Therapeutics, Inc.

NASDAQ:VERA

Intrinsic Alpha fair value

Locked

Current Price

$25.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.